Isoform Specificity of Progesterone Receptor Antibodies

FABRIS, VICTORIA; ABASCAL, MARIA FLORENCIA; GIULIANELLI, SEBASTIÁN; MAY, MARÍA; SEQUEIRA, GONZALO; JACOBSEN, BRITTA; LOMBÈS,MARC; HAN, JULIE; TRAN, LUAN; MOLINOLO, ALFREDO; LANARI, CLAUDIA

The Journal of Pathology: Clinical Research

JOHN WILEY & SONS LTD

Lugar: Londres; Año: 2017 vol. 3 p. 227 - 233

Progesterone receptors (PR) are prognostic and predictive biomarkers in hormone-dependent cancers. Two main PR isoforms have been described, PRB and PRA, that differ only in that PRB has 164 extra N-terminal amino acids. It has been reported that several antibodies empirically exclusively recognize PRA in formalin-fixed paraffin-embedded tissues (FFPE). To confirm these findings, we used human breast cancer xenograft models, T47D-YA and -YB cells expressing PRA or PRB respectively, MDA-MB-231 cells modified to synthesize PRB, and MDA-MB-231/iPRAB cells which can bi-inducibly express either PRA or PRB. Cells were injected into immunocompromised mice to generate tumours exclusively expressing PRA or PRB. PR isoform expression was verified using immunoblots. FFPE samples from the same tumours were studied by immunohistochemistry using H-190, clone 636, clone 16, and Ab-6 anti-PR antibodies, the latter exclusively recognizing PRB. Except for Ab-6, all antibodies displayed a similar staining pattern. Our results indicate that clones 16, 636 and the H-190 antibody recognize both PR isoforms. They point to the need for more stringency in evaluating the true specificity of purported PRA-specific antibodies as the PRA/PRB ratio may have prognostic and predictive value in breast cancer.